BEKE-W
02423
XIAOMI-W
01810
ALI HEALTH
00241
JD HEALTH
06618
MEITUAN-W
03690
(FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | ---- | ---- | -5.40%37.66B | ---- | ---- | ---- | 4.31%39.81B | ---- | -9.01%76.61B | ---- |
Special items of operating revenue | ---- | 1.82%59.97B | ---- | -7.06%18.62B | ---- | -4.02%58.9B | ---- | 4.55%20.03B | ---- | -11.41%61.37B |
Operating income | 6.19%63.79B | 1.82%59.97B | -5.40%37.66B | -7.06%18.62B | -21.59%60.07B | -4.02%58.9B | 4.31%39.81B | 4.55%20.03B | -9.01%76.61B | -11.41%61.37B |
Operating expenses | ||||||||||
Gross profit | ||||||||||
Administrative expenses | ---- | 4.62%-20.14B | ---- | 15.59%-6.18B | ---- | -4.69%-21.11B | ---- | -19.77%-7.32B | ---- | 0.65%-20.17B |
Employee expense | ---- | ---- | 8.26%-9.81B | ---- | ---- | ---- | -3.58%-10.7B | ---- | -1.98%-21.17B | ---- |
Depreciation and amortization | ---- | ---- | -17.30%-858.81M | ---- | ---- | ---- | -12.51%-732.14M | ---- | -238.22%-1.35B | ---- |
Impairment and provision | ---- | 1,620.70%499.46M | 190.29%346.17M | 108.29%19.75M | ---- | 89.67%-32.84M | -240.38%-383.39M | -156.11%-238.26M | 105.25%184.01M | 87.80%-317.99M |
-Other impairment is provision | ---- | 1,620.70%499.46M | 190.29%346.17M | 108.29%19.75M | ---- | 89.67%-32.84M | -240.38%-383.39M | -156.11%-238.26M | 105.25%184.01M | 87.80%-317.99M |
Operating interest expense | ---- | -5.61%-13.83B | -6.94%-9.21B | -3.85%-4.86B | ---- | -13.40%-13.09B | -12.24%-8.61B | -18.78%-4.68B | 0.13%-15.22B | -0.77%-11.55B |
Special items of operating profit | ---- | -66.56%-4.27B | 4.47%-4.25B | -146.07%-886.37M | ---- | 61.48%-2.56B | -24.23%-4.45B | 84.64%-360.22M | 19.16%-10.4B | 37.83%-6.65B |
Operating profit | 9.16%28.51B | 0.92%22.01B | -6.78%13.73B | -9.50%6.63B | -7.65%26.11B | -2.62%21.81B | -5.74%14.73B | 3.37%7.33B | -8.80%28.28B | -6.19%22.4B |
Share of profits of associates | ---- | ---- | -39.46%217.38M | ---- | ---- | ---- | 240.82%359.07M | ---- | -24.22%645.66M | ---- |
Share of profit from joint venture company | ---- | ---- | -80.62%1.16M | ---- | ---- | ---- | -76.63%5.97M | ---- | -26.53%27.73M | ---- |
Special items of earning before tax | ---- | -859.98%-89.17M | ---- | -145.32%-2.85M | ---- | -94.27%11.73M | ---- | 158.81%6.29M | ---- | 558.98%204.9M |
Earning before tax | 8.53%28.42B | 0.46%21.93B | -7.59%13.95B | -9.62%6.63B | -9.55%26.19B | -3.46%21.82B | -1.97%15.1B | 3.62%7.34B | -9.23%28.95B | -5.16%22.61B |
Tax | ---- | 5.94%-4.47B | 11.23%-2.97B | 13.91%-1.47B | ---- | 12.04%-4.76B | 11.71%-3.35B | -2.71%-1.71B | 14.04%-6.78B | 2.39%-5.41B |
After-tax profit from continuing operations | 2.24%17.45B | -6.55%10.98B | -8.31%5.16B | -0.76%17.07B | 1.22%11.75B | 3.90%5.63B | -7.65%22.17B | -6.00%17.2B | ||
Earning after tax | 2.24%17.45B | -6.55%10.98B | -8.31%5.16B | -0.76%17.07B | 1.22%11.75B | 3.90%5.63B | -7.65%22.17B | -6.00%17.2B | ||
Minority profit | ---- | -0.36%652.05M | -7.61%412.17M | -4.43%203.57M | ---- | 3.70%654.38M | 7.64%446.14M | 12.17%213.01M | -5.97%851.37M | -3.01%631.05M |
Profit attributable to shareholders | 10.06%21.7B | 2.35%16.8B | -6.51%10.57B | -8.47%4.96B | -7.49%19.72B | -0.93%16.41B | 0.98%11.31B | 3.60%5.42B | -7.72%21.32B | -6.11%16.57B |
Basic earnings per share | 8.46%1.41 | 0.93%1.09 | -8.00%0.69 | -11.11%0.32 | -8.45%1.3 | -1.82%1.08 | -1.32%0.75 | 0.00%0.36 | -15.98%1.42 | -19.12%1.1 |
Diluted earnings per share | 0.93%1.09 | -8.00%0.69 | -11.11%0.32 | -1.82%1.08 | -1.32%0.75 | 0.00%0.36 | -15.98%1.42 | -19.12%1.1 | ||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | IAS | CAS (2007) | CAS (2007) | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.